Uptake, safety, and effectiveness of inactivated influenza vaccine in patients with inflammatory bowel disease: a nationwide study in the UK using data from the Clinical Practice Research Datalink.
Nakafero, G.; Grainge, M. J.; Card, T.; Mallen, C. D.; Nguyen-Van-Tam, J.; Abhishek, A.
Show abstract
ObjectiveWe investigated UK wide inactivated influenza vaccine (IIV) uptake in adults with inflammatory bowel disease (IBD), the association between vaccination against influenza and IBD flare, and the effectiveness of IIV in preventing morbidity and mortality. DesignData for adults with IBD prior to 1st September 2018 were extracted from the Clinical Practice Research Datalink (CPRD) Gold, a database of electronic health records originated during routine care of patients in the UK. It is linked to hospitalization and mortality records. We calculated the proportion of patients vaccinated against seasonal influenza in the 2018-2019 influenza cycle. To investigate vaccine effectiveness, we calculated propensity score (PS) for vaccination and undertook Cox proportional hazard regression with inverse-probability treatment weighting on PS. We employed self-controlled case series (SCCS) to investigate the association between vaccination and IBD flare. ResultsData for 13,631 IBD patients (50.4% male, mean age 52.9 years) were included. Fifty percent were vaccinated during the influenza cycle while 32.1% were vaccinated before influenza virus circulated in the community. Vaccination was associated with a non-significant reduction in hospitalisation for pneumonia (aHR (95%CI) 0.52 (0.20-1.37), including in the influenza active period (aHR (95%CI) 0.48 (0.18-1.27)). Administration of the influenza vaccine was not associated with IBD flare. ConclusionThe uptake of influenza vaccine is low in IBD patients and the majority are not vaccinated before influenza virus circulates in the community. Vaccination with the IIV is not associated with IBD flare. These findings add to the evidence to promote vaccination in patients with IBD. Key messagesO_ST_ABSWhat is already known on the topicC_ST_ABSO_LIInactivated influenza vaccine is recommended in people with IBD treated with immune suppressing drugs. C_LIO_LIConcerns about influenza vaccine causing IBD flare and lack of data on the effectiveness of influenza vaccine in people with IBD are barriers to seasonal influenza vaccination in this population. C_LI What this study addsO_LIThe uptake of seasonal influenza vaccination is low in IBD patients. C_LIO_LISeasonal influenza vaccination is not associated with IBD flare and is more likely to prevent serious complications of influenza in this population. C_LI How this study might affect research, practice, or policyO_LIThis study provides new data on the uptake, effectiveness, and safety of influenza vaccine in people with IBD and adds to the accumulating evidence to promote vaccination in this population. C_LI
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines 94%
- Maintenance therapy with infliximab or vedolizumab in inflammatory bowel disease is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic 94%
- Optimising Early Management of Acute Severe Ulcerative Colitis in the Biologics Era: Admission Model for Intensification of Therapy in Acute Severe Colitis (ADMIT–ASC) 93%
Similar papers in this journal
Similar papers in this journal
- Effectiveness and Safety of Combining Tofacitinib with a Biologic in Patients with Refractory Inflammatory Bowel Diseases 93%
- Adverse Events Following SARS-CoV-2 mRNA Vaccination Among Patients with Inflammatory Bowel Disease 93%
- Appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis 93%
Similar papers in this journal
- Predictors of symptom trajectory in newly diagnosed ulcerative colitis: a 3-year follow-up cohort study 92%
- An extremes of phenotype approach confirms significant genetic heterogeneity in patients with ulcerative colitis. 91%
- Whole blood DNA methylation changes are associated with anti-TNF drug concentration in patients with Crohn’s disease 91%
Similar papers in this journal
- Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies; A Multi-Center Prospective Study 94%
- COVID-19 Vaccine Booster Dose Willingness Among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional Study 93%
- Persistent health issues, adverse events of significant concern, and effectiveness of COVID-19 vaccination- findings from a real-world cohort study of healthcare workers in north India 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.